What is the generic name?

MOXETUMOMAB PASUDOTOX

What is the Trade Name for MOXETUMOMAB PASUDOTOX?

LUMOXITI

What are the Indications for MOXETUMOMAB PASUDOTOX?

• 1 INDICATIONS AND USAGE LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). Limitations of Use LUMOXITI is not recommended in patients with severe renal impairment (CrCl ‚⧠29 mL/min) [see Dosage and Administration (2.3) , Warnings and Precautions (5.3) , and Use in Specific Populations (8.5) ] . LUMOXITI is a CD22-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). (1) Limitations of Use Not recommended in patients with severe renal impairment (CrCl ‚⧠29 mL/min). (1)

References: https://open.fda.gov/